CN108522425A - 一种前列腺癌高脂饮食模型的建立方法及其用途 - Google Patents
一种前列腺癌高脂饮食模型的建立方法及其用途 Download PDFInfo
- Publication number
- CN108522425A CN108522425A CN201710126711.7A CN201710126711A CN108522425A CN 108522425 A CN108522425 A CN 108522425A CN 201710126711 A CN201710126711 A CN 201710126711A CN 108522425 A CN108522425 A CN 108522425A
- Authority
- CN
- China
- Prior art keywords
- mouse
- prostate cancer
- model
- tramp
- fat diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 47
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000013238 high-fat diet model Methods 0.000 title claims abstract description 16
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 58
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 238000010172 mouse model Methods 0.000 claims abstract description 15
- 235000021590 normal diet Nutrition 0.000 claims abstract description 12
- 210000002307 prostate Anatomy 0.000 claims abstract description 10
- 230000004069 differentiation Effects 0.000 claims abstract description 8
- 230000000474 nursing effect Effects 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000002474 experimental method Methods 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 13
- 238000011160 research Methods 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 4
- 239000003098 androgen Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 108010042121 probasin Proteins 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000011740 C57BL/6 mouse Methods 0.000 claims description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims description 2
- 235000012041 food component Nutrition 0.000 claims description 2
- 239000005417 food ingredient Substances 0.000 claims description 2
- 239000004459 forage Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 230000007246 mechanism Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 235000009200 high fat diet Nutrition 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 238000012546 transfer Methods 0.000 abstract description 4
- 238000007877 drug screening Methods 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 9
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Animal Husbandry (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
Abstract
本发明属生物医药和基因工程领域,涉及一种建立TRAMP小鼠高脂饮食模型的方法及其在用于预防和治疗前列腺癌过程研究平台中的应用。本发明建立以40%脂肪供能饲料为干预措施、以转基因前列腺癌小鼠(TRAMP)为基础的前列腺癌肥胖模型,该模型小鼠前列腺组织肿瘤形成,分化和转移均高于普通饲料喂养的TRAMP小鼠,通过物理学测量、血液生化检查、影像学检查等综合手段,评估前列腺癌肥胖模型的稳定性,建立一个前列腺癌发生与发展中肥胖相关因素的客观、统一、稳定、精准的模型和实验平台,该模型能较好反映高脂饮食对前列腺癌发生发展的影响,在前列腺癌机制研究以及相应的药物筛选、药效评估领域具有广泛的应用价值。
Description
技术领域
本发明属生物医药和基因工程领域,涉及高脂饮食模型的建立方法,具体涉及一种建立TRAMP小鼠高脂饮食模型的方法及其在用于预防和治疗前列腺癌过程中的应用。
背景技术
转基因前列腺癌小鼠(transgenic adenocarcinoma of mouse prostate,TRAMP)模型是目前最常使用的转基因前列腺癌模型之一,1995年Greenberg等首先报道该动物模型的建立,其包括,通过转基因方法将受雄激素调控的probasin启动子结合猴病毒40(SV40)T抗原转入小鼠,特异性诱导小鼠前列腺发生肿瘤,T抗原在4-6周即开始表达,SV40产生的肿瘤蛋白可阻断抑癌基因P53和RB通路,从而导致肿瘤形成,以及病理进展与人前列腺癌类似(Greenberg NM et al. 1995, Gingrich JR et al. 1996)。
资料显示,高脂肪、高蛋白、高热量摄入是西方饮食习惯的主要特点,长期高脂饮食会导致代谢综合征(metabolic syndrome, MS)的发生,即肥胖、高血压、高血糖、血脂异常等多种代谢危险因素在同一个体中同时存在的临床症候群,包括胰岛素抵抗、代偿性高胰岛素血症、激素水平失调、血液高凝和全身慢性炎症状态等(Pu YS et al. 2004)。众多研究发现高脂饮食与前列腺癌发生进展密切相关(Lund HL et al. 2006, De Nunzio Cet al. 2011),表现为增加前列腺癌的发生率,并增加肿瘤的侵袭和转移。研究显示,高脂饮食和肥胖促进前列腺癌发生和进展,其机制是复杂且互相关联的,在众多机制中,机体循环雄激素水平(Severi G et al. 2006)、胰岛素及胰岛素样生长因子-1(insulin-likegrowth factor-1, IGF-1)( Rowlands MA et al. 2012)、炎症因子(Kundu JK et al.2008)、脂肪因子(Rajala MW et al. 2003)等表达水平的改变越来越受到重视。研究表明高脂饮食导致肥胖,会造成体内白色脂肪组织慢性炎症过程,表现为脂肪细胞肥大增生,且前脂肪细胞增多,直接导致局部和体循环的脂肪因子增多,介导免疫过程和促炎、促瘤微环境(Vona-Davis L et al. 2009);白色脂肪组织可以分泌超过 50 种不同的细胞因子(Balistreri CR et al. 2010),包括 IL-6、 IL-8、 IL-1β、 IL-17、 TNF-α、 VEGF、 CCL-2、 CCL-5等,有助于促有丝分裂、促血管新生、召集免疫细胞,除此之外,还具有刺激上皮间质转变(epithelial-mesenchymal transition, EMT)、增加肿瘤细胞侵袭、增加脂肪细胞和肿瘤干细胞的交互作用等;研究进一步发现,肥胖者中除局部脂肪组织中细胞因子含量发生变化,血清中循环的促炎症细胞因子水平也有明显上升,如TNF-α、IL-6、IL-8、VEGF等,可能对远处促瘤转移环境的形成造成重要影响。
目前业内关于肥胖和前列腺癌诊断、病理结局、预后等关系尚未明确,尤其在亚洲人群中报道较少;且肥胖和高脂饮食对前列腺癌影响的相关机制尚未完全阐明,尤其是高脂饮食介导的体内循环细胞因子变化。基于此,本申请的发明人拟提供一种TRAMP小鼠高脂饮食模型的建立方法,进一步用于研究前列腺癌与代谢综合征的关系,预防和治疗等等。
发明内容
本发明的目的在于居于现有技术的现状,提供一种转基因前列腺癌小鼠(transgenic adenocarcinoma of mouse prostate,TRAMP)小鼠高脂饮食模型的建立方法,进一步用于建立前列腺癌与代谢综合征的关系,预防和治疗等研究平台。
鉴于现有技术公开的的不同规格饲料诱导小鼠肥胖的效果相差较大,且因缺乏客观、统一、稳定、精准的前列腺癌肥胖模型,使得不同研究之间的可比性降低,可信度不高;另外,传统的细胞学实验难以模拟肥胖引起的内环境变化,而利用裸鼠移植瘤模型进行肥胖建模又难以模仿前列腺癌的发生过程等等缺陷;
本发明建立以40%脂肪供能饲料为干预措施、以转基因前列腺癌小鼠(TRAMP)为基础的前列腺癌肥胖模型,通过物理学测量、血液生化检查、影像学检查等综合手段,评估前列腺癌肥胖模型的稳定性,建立一个为研究前列腺癌发生与发展中肥胖相关因素的客观、统一、稳定、精准的模型和实验平台,为进一步深入研究前列腺癌发生与发展的机制奠定基础。
本发明的一种转基因前列腺癌小鼠高脂饮食模型的建立方法,其包括,构建TRAMP前列腺癌小鼠模型以及构建TRAMP小鼠高脂饮食模型。
本发明中,基于C57BL/6品系的小鼠模型建立前列腺癌肥胖小鼠模型;
本发明中,通过转基因方法将受雄激素调控的probasin启动子结合猴病毒40(SV40)T抗原转入小鼠,特异性诱导小鼠前列腺发生肿瘤。
具体的,本发明的一种前列腺癌高脂饮食模型的建立方法,通过以下技术方案实现:
1)小鼠出生后即断趾进行基因检测,
基因型检测采用PCR方法,采用Sv40引物和tcrd引物作为内参,Sv40上游引物CAGAG-CAGAATTGTGGAGTGG,下游引物GGACAAACCA-CAACTAGAATGCAGTG,内参 tcrd 上游引物:CAAATGTTGCTTGTCTGGTG,下游引物:GTCAGTC-GAGTGCACAGTTT,PCR产物行1%琼脂糖凝胶电泳,根据片段大小确定基因型;
子代小鼠均行基因型检测,保留带有目标基因雄鼠,其余小鼠按常规另处理;
2)采用携带基因的雄鼠为实验所需小鼠,
小鼠出生20天断奶后分笼,并随机分入实验组(高脂饲料喂养组)和对照组(普通饲料喂养组)进行饲料喂养,高脂饲料成分如表1所示;
表1:高脂饲料信息
结果显示,本方法中通过喂养TRAMP小鼠40%脂肪供能的肥胖诱导饲料,能显著地促进TRAMP小鼠体重的增加,且具有如下有益的技术效果:
(1)、本发明提供的TRAMP小鼠肥胖模型建立方法建模操作简单,成功率高(超过80%);
(2)、本发明提供的TRAMP小鼠肥胖模型不依赖于宿主免疫缺陷或特定的遗传学背景;
(3)、本发明提供的TRAMP小鼠肥胖模型中的组织与血清标本可用于检测多种肿瘤标志物,比较实验组与对照组差异,用途广泛;
(4)、本发明建立的的TRAMP小鼠肥胖模型可进一步用于抗肿瘤药物筛选和药物安全性评价等,如相应的药物筛选、药效评估等研发领域。
本发明提供了一种简便实用的转基因前列腺癌小鼠高脂饮食模型的建立方法,可进一步用于建立前列腺癌与代谢综合征的关系,预防和治疗等研究平台。
附图说明
图1显示TRAMP小鼠基因型检测结果,
其中,根据PCR结果,以tcrd作为内参,见1、2号小鼠在474bp阳性条带,验证SV40 Tag阳性,即该TRAMP小鼠携带SV40 Tag基因;而3、4号小鼠为阴性,即该TRAMP小鼠未携带SV40Tag基因。
图2显示大体解剖:TRAMP前列腺癌局部巨大包块、精囊侵犯。
图3显示Micro-CT:TRAMP前列腺癌局部占位,肺部转移灶。
图4 TRAMP小鼠前列腺HE染色(200X光镜),确诊为前列腺癌,证实成瘤。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。除非另有描述,本发明的实施将采用免疫学、分子生物学、微生物学和重组DNA等常规技术,这些均是本领域技术人员所知的。这些技术在下列文献中有完整的描述:例如,Sambrook《分子克隆实验指南》第2版(1989);《DNA克隆》第I和II卷(D.N.Glover编辑,1985);《寡核苷酸合成》(M.J. Gait编辑,1984);以及《实验免疫学手册》I-IV卷(D.C. Weir和C.C. Blackwell编辑,1986)。或者,可按照试剂生产商所提供的说明书进行。
实施例1:构建TRAMP前列腺癌小鼠模型
采用TRAMP 小鼠(transgenic adenocarcinoma of mouse prostate,TRAMP,购自美国Jackson 实验室,于复旦大学发育生长研究所饲养并配种繁殖),出生后即刻断趾行基因检测,将断趾置于 EP 管内,加入 500 ul 裂解液(50mM Tris, 100mM EDTA, 0.5% SDS)和25ul 蛋白酶 K(10mg/ml)后混匀,55d℃温箱过夜;次日加入 500ul 酚氯仿, 13200 转/分离心两分钟,弃去沉淀,将 200ul上清移至 EP 管,加入 200ul 酚氯仿混匀, 13200 转/分离心 1 分钟,再次弃去沉淀,将 100ul 上清转移至 EP 管,加入无水酒精 250ul 及 3M醋酸钠 25ul 混匀,13200 转/分离心 1 分钟,弃上清,沉淀用 75%酒精洗两次后于室温10 分钟晾干,后加入 100ul TE 溶解, PCR 扩增目的基因,凝胶电泳检测小鼠基因型,TRAMP小鼠基因检测采用 Sv40 引物和 Tcrd 引物作为内参;
PCR 步骤:模板在 PCR 仪上以 94℃预加热五分钟,使模板 DNA 充分变性,进入扩增循环。首先重复扩增循环 12 次,每一个循环中先于 94℃保持 20 秒使模板变性,后降温至复性温度 64℃(每个循环减少 0.5℃),保持 30 秒,使引物与模板充分退火; 72℃保持35 秒,使引物在模板上延伸,合成 DNA,完成单次循环;其次重复扩增循环 25 次,在每一个循环中,先于 94℃保持 20 秒使模板变性,后将温度降到复性温度 58℃,保持 30 秒,使引物与模板充分退火;在 72℃保持 35 秒,使引物在模板上延伸,合成 DNA,完成单次循环;经过上述扩增循环使得扩增的 DNA 片段大量累积,最后在 72℃保持 7 分钟,使产物延伸完整,4℃保存, PCR 产物行 1%琼脂糖凝胶电泳,根据片段大小确定基因型,子代小鼠均行基因型检测,仅保留带有目的基因雄鼠。
实施例2:构建TRAMP小鼠高脂饮食模型
经基因型鉴定,仅保留携带目的基因雄鼠;小鼠出生 20 天断奶后分笼,分对照组及实验组后分别予以普通饲料和高脂饲料喂养,饲料成分如表1所示,小鼠饲料喂养起自断奶当天至处死取材前日,动物室内温度维持于 23℃±1℃,湿度维持于 60%±10%,小鼠自由饮水、进食,采用 12h 明暗交替照明,每周换 3 次水、 3 次垫料,处死前禁食不禁水 10 小时,于20w、 24w、 28w 时,分3 批处死小鼠;
普通饲料和高脂饲料(如表1所示高脂饲料)喂养组TRAMP 小鼠的基本情况及肿瘤形成、肿瘤分化、肿瘤转移情况如表 2 所示,结果显示,随着周龄上升,普通饲料组 TRAMP 小鼠和高脂饲料组 TRAMP 小鼠均出现体重上升和体脂上升,而同周龄时高脂饲料组 TRAMP体重高于普通饲料组,20和24周体脂高于普通饲料组,各组间血糖未见明显差异;
在肿瘤形成方面,肿瘤形成比例随周龄增加而上升;对于同周龄时,高脂组在 20 周时高于普通饲料组, 24 周和 28 周时两组未见明显差异;
肿瘤分化方面,随周龄增加各组肿瘤分化变差,高分化比例下降,而中低分化比例增加;对于同周龄时,高脂组分化较普通饲料组差;
肿瘤转移方面,随周龄增加各组肿瘤转移率均上升;对于同周龄时, 20 周与 24 周时两组未见明显差异,28 周时高脂组高于普通饲料组。
表1:高脂饲料信息
表2 不同饲料喂养TRAMP 小鼠基本情况及肿瘤形成比较
本发明提供了TRAMP小鼠高脂饮食模型的建立方法。该模型小鼠前列腺组织肿瘤形成,分化和转移均高于普通饲料喂养的TRAMP小鼠。因此,该模型能够较好反映高脂饮食对前列腺癌发生发展的影响,从而在前列腺癌机制研究以及相应的药物筛选、药效评估等研发领域具有广泛的应用价值。
SEQUENCE LISTING
<110> 复旦大学附属华山医院
<120> 一种前列腺癌高脂饮食模型的建立方法及其用途
<130> 20170306
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 21
<212> DNA
<213> Sv40上游引物
<400> 1
cagagcagaa ttgtggagtg g 21
<210> 2
<211> 26
<212> DNA
<213> Sv40下游引物
<400> 2
ggacaaacca caactagaat gcagtg 26
<210> 3
<211> 20
<212> DNA
<213> 内参tcrd上游引物
<400> 3
caaatgttgc ttgtctggtg 20
<210> 4
<211> 20
<212> DNA
<213> 内参tcrd下游引物
<400> 4
gtcagtcgag tgcacagttt 20
Claims (7)
1.一种前列腺癌高脂饮食模型的建立方法,其特征在于,其包括,构建TRAMP前列腺癌小鼠模型以及构建TRAMP小鼠高脂饮食模型;
其中,基于C57BL/6品系的小鼠模型建立前列腺癌肥胖小鼠模型;
通过转基因方法将受雄激素调控的probasin启动子结合猴病毒40(SV40)T抗原转入小鼠,特异性诱导小鼠前列腺发生肿瘤。
2.按权利要求1所述的方法,其特征在于,所述的构建TRAMP前列腺癌小鼠模型方法中包括:
1)小鼠基因检测,
基因型检测采用PCR方法,采用Sv40引物和tcrd引物作为内参,
Sv40上游引物CAGAG-CAGAATTGTGGAGTGG,
下游引物GGACAAACCA-CAACTAGAATGCAGTG,
内参tcrd上游引物:CAAATGTTGCTTGTCTGGTG,
下游引物:GTCAGTC-GAGTGCACAGTTT,
PCR产物行1%琼脂糖凝胶电泳,根据片段大小确定基因型;
子代小鼠均行基因型检测,保留带有目标基因雄鼠;
2)采用携带目标基因的雄鼠为高脂饲料实验所需小鼠。
3.按权利要求所述1的方法,其特征在于,所述的建立前列腺癌肥胖小鼠模型方法中包括:
采用出生20天断奶后的携带目标基因的雄鼠小鼠,随机分高脂饲料喂养组入实验组和普通饲料喂养组对照组进行饲料喂养,其中,高脂饲料成分如表1所示;
表1:高脂饲料信息
数周后比较试验组与对照组的基本情况及肿瘤形成、肿瘤分化、肿瘤转移情况,确定构建获得的前列腺癌高脂饮食模型。
4.按权利要求1所述的方法,其特征在于,所述的构建前列腺癌肥胖小鼠模型不依赖于宿主免疫缺陷或特定的遗传学背景。
5.按权利要求1所述的方法,其特征在于,所述的构建的前列腺癌肥胖小鼠模型的组织与血清标本在用于制备检测肿瘤标志物的制剂中的用途。
6.按权利要求1所述的方法,其特征在于,所述的构建的前列腺癌肥胖小鼠模型在用于筛选抗肿瘤药物和药物安全性评价中的用途。
7.按权利要求1所述的方法,其特征在于,所述的构建的前列腺癌肥胖小鼠模型在用于建立前列腺癌与代谢综合征的关系,预防和治疗研究平台中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710126711.7A CN108522425A (zh) | 2017-03-06 | 2017-03-06 | 一种前列腺癌高脂饮食模型的建立方法及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710126711.7A CN108522425A (zh) | 2017-03-06 | 2017-03-06 | 一种前列腺癌高脂饮食模型的建立方法及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108522425A true CN108522425A (zh) | 2018-09-14 |
Family
ID=63488607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710126711.7A Pending CN108522425A (zh) | 2017-03-06 | 2017-03-06 | 一种前列腺癌高脂饮食模型的建立方法及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108522425A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103060434A (zh) * | 2012-10-19 | 2013-04-24 | 卫生部北京医院 | 一种预测前列腺癌易感性的试剂和方法 |
US20130142861A1 (en) * | 2011-12-05 | 2013-06-06 | National Yang Ming University | Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis |
CN104705258A (zh) * | 2015-02-10 | 2015-06-17 | 陕西师范大学 | 一种饮食诱导胰岛素抵抗模型的构建方法及应用 |
CN105850867A (zh) * | 2016-03-28 | 2016-08-17 | 大连大学 | 一种非酒精性脂肪肝小鼠模型的建立方法 |
CN106070064A (zh) * | 2016-07-13 | 2016-11-09 | 武汉大学 | 一种多囊卵巢综合征伴2型糖尿病大鼠模型的构建方法 |
-
2017
- 2017-03-06 CN CN201710126711.7A patent/CN108522425A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130142861A1 (en) * | 2011-12-05 | 2013-06-06 | National Yang Ming University | Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis |
CN103060434A (zh) * | 2012-10-19 | 2013-04-24 | 卫生部北京医院 | 一种预测前列腺癌易感性的试剂和方法 |
CN104705258A (zh) * | 2015-02-10 | 2015-06-17 | 陕西师范大学 | 一种饮食诱导胰岛素抵抗模型的构建方法及应用 |
CN105850867A (zh) * | 2016-03-28 | 2016-08-17 | 大连大学 | 一种非酒精性脂肪肝小鼠模型的建立方法 |
CN106070064A (zh) * | 2016-07-13 | 2016-11-09 | 武汉大学 | 一种多囊卵巢综合征伴2型糖尿病大鼠模型的构建方法 |
Non-Patent Citations (1)
Title |
---|
许华: "IGF-1相关通路在高脂饮食对前列腺癌发生及进展影响中的作用", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gertler et al. | Metastasis: tumor cells becoming MENAcing | |
CN105803088B (zh) | 一组检测Kras基因突变的引物和探针及其试剂盒 | |
CN104593372B (zh) | 一种检测胰腺导管癌的核酸适配体、试剂盒及方法 | |
CN102667484A (zh) | 识别黑素瘤肿瘤细胞的生物标记 | |
CN109423517B (zh) | 外泌体在肿瘤诊断、治疗和预后评估中的用途 | |
CN110004250A (zh) | 一种非洲猪瘟病毒lamp可视化检测试剂盒 | |
CN110423819A (zh) | 一种参与人结直肠癌增殖和耐药的lncRNA及其应用 | |
CN106070063A (zh) | 带abcb4的转基因斑马鱼系及其建立方法 | |
CN109837345A (zh) | 检测小鼠细胞残留dna的引物及方法 | |
CN113599524A (zh) | Hnrnpc和rbmx作为靶点在制备治疗小细胞肺癌的产品中的应用 | |
CN105412944A (zh) | miR-451a细胞在非小细胞肺癌中的作用 | |
CN108522425A (zh) | 一种前列腺癌高脂饮食模型的建立方法及其用途 | |
CN106754938B (zh) | 一种检测人肾透明细胞癌细胞的核酸适体及其在制备检测制剂中的应用 | |
CN107904307A (zh) | Nfi转录因子在食管鳞癌中的应用 | |
CN101168566A (zh) | 抗肿瘤特异性标志蛋白ts/medp的抗体制备及用途 | |
CN105985961B (zh) | 抑制EGFR基因表达的siRNA及其应用 | |
CN108998532A (zh) | 一种直肠腺癌的诊治标志物 | |
CN103468799B (zh) | Eif5a2在制备治疗食管鳞状细胞癌制剂中的应用 | |
CN106635999A (zh) | Mmhrl1转基因小鼠肝肿瘤细胞系的建立及应用 | |
CN104878076B (zh) | 一种Her‑2基因的cDNA原位杂交探针及其制备方法 | |
CN114225036A (zh) | Atxn1蛋白作为靶点在制备治疗、预防或诊断髓母细胞瘤的药物或试剂盒中的应用 | |
CN105567832B (zh) | 一种非疾病的诊断和治疗目的的微生物耐药性基因的检测方法 | |
CN105506088B (zh) | 鸡B亚群禽白血病抗性分子标记tvb3667-3668insAG及其分子诊断方法 | |
CN107858428A (zh) | 一种与食管胃交界腺癌相关的生物标志物及其应用 | |
CN108220381A (zh) | 试剂在制备药物中的用途以及筛选药物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180914 |
|
RJ01 | Rejection of invention patent application after publication |